肿瘤细胞治疗研究
英文原题：CAR-T cell therapy as an approach for pediatric hematological malignancies in regenerative therapy: Current status and clinical outcomes.
CAR-T cell therapy as an approach for pediatric hematological malignancies in regenerative therapy: Current status and clinical outcomes.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
放射治疗、化疗和手术多年来一直是标准的癌症治疗方法。即使采用这些治疗，大多数肿瘤的预后仍然很差。在关键的 CD19-CART 试验中，完全缓解率在 65% 至 90% 之间，CAR-T 细胞疗法彻底改变了复发/难治性 B 细胞急性淋巴细胞白血病（B-ALL）儿科患者的治疗模式。血液系统肿瘤对 CAR-T 反应良好。首个 CAR-T 于 2017 年获得 FDA 批准用于治疗 B-ALL。同年 10 月，FDA 批准 CAR-T 用于治疗 B 细胞淋巴瘤。近年来，研究集中于 CAR-T 以提高和改善治疗效果。随着这种新药的出现，新的毒性特征和治疗限制也随之出现，需要合作组试验、新的管理策略和毒性共识分级系统。本文的主要主题将是 CAR-T 治疗在儿科 B 细胞 ALL 中的引入，以及既往和正在进行的试验。
我们还将讨论针对各种儿科癌症的 CAR-T 治疗试验。由于 CAR-T 治疗有可能引起严重毒性，安全程序和密切观察至关重要。
Radiation therapy, chemotherapy, and surgery have been the standard cancer treatment approaches for many years. Even with these treatments, the majority of tumors still have a dismal prognosis. With complete remission rates ranging from 65% to 90% in the crucial CD19-CART trials, chimeric antigen receptor T-cell (CART) therapy has revolutionized the treatment paradigm for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Hematological tumors have responded well to CART.
The first CART was authorized by the FDA in 2017 to treat B-ALL. The FDA authorized CART to treat B-cell lymphoma in October of that year. In recent years, research has focused on CART to increase and improve the therapeutic effect.
New toxicity profiles and treatment constraints have also surfaced with this new medicine, calling for cooperative group trials, new management strategies, and toxicity consensus grading systems. The introduction of CART treatment for pediatric B-cell ALL will be the main topic of this article, along with previous and ongoing trials.
We will also talk about CART therapy trials for various pediatric cancers. Safe procedures and close observation are essential since CART treatment has the potential to cause serious toxicities.
MEMBER ACCOUNT
登录成功会直接打开下一页。
